We investigated the value of the expression of CMTM6 or PD-L1, the coexpression of CMTM6 and PD-L1, and their expression in ICs (CD4+, CD8+, CD68+ and CD163+) in predicting the responsiveness of CRC patients to PD-1/PD-L1 inhibitors. This evidence concerns the gene CD68 and colorectal carcinoma.